Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

BACKGROUND: In the AVAGAST study, fluoropyrimidine and cisplatin plus bevacizumab did not significantly improve overall survival (OS) versus fluoropyrimidine and cisplatin plus placebo in patients with advanced gastric cancer. Geographic differences in efficacy were observed in AVAGAST, but the stud...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gastric Cancer
Main Authors: Shen, Lin, Li, Jin, Xu, Jianming, Pan, Hongming, Dai, Guanghai, Qin, Shukui, Wang, Liwei, Wang, Jinwan, Yang, Zhenzhou, Shu, Yongqian, Xu, Ruihua, Chen, Lei, Liu, Yunpeng, Yu, Shiying, Bu, Lilian, Piao, Yongzhe
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Japan 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4544634/
https://ncbi.nlm.nih.gov/pubmed/24557418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-014-0351-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados